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Summary
Background Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and 
prophylactic cranial irradiation, have persistent intra thoracic disease. We assessed thoracic radiotherapy for treatment 
of this patient group.
Methods We did this phase 3 randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 in the UK, three in 
Norway, and one in Belgium. We enrolled patients with WHO performance score 0–2 and conﬁ rmed ES-SCLC who 
responded to chemotherapy. They were randomly assigned (1:1) to receive either thoracic radiotherapy (30 Gy in 
ten fractions) or no thoracic radiotherapy. All underwent prophylactic cranial irradiation. The primary endpoint was 
overall survival at 1 year in the intention-to-treat population. Secondary endpoints included progression-free survival. 
This study is registered with the Nederlands Trial Register, number NTR1527.
Findings We randomly assigned 498 patients between Feb 18, 2009, and Dec 21, 2012. Three withdrew informed 
consent, leaving 247 patients in the thoracic radiotherapy group and 248 in the control group. Mean interval between 
diagnosis and randomisation was 17 weeks. Median follow-up was 24 months. Overall survival at 1 year was not 
signiﬁ cantly diﬀ erent between groups: 33% (95% CI 27–39) for the thoracic radiotherapy group versus 28% (95% CI 
22–34) for the control group (hazard ratio [HR] 0·84, 95% CI 0·69–1·01; p=0·066). However, in a secondary analysis, 
2-year overall survival was 13% (95% CI 9–19) versus 3% (95% CI 2–8; p=0·004). Progression was less likely in the 
thoracic radiotherapy group than in the control group (HR 0·73, 95% CI 0·61–0·87; p=0·001). At 6 months, 
progression-free survival was 24% (95% CI 19–30) versus 7% (95% CI 4–11; p=0·001). We recorded no severe toxic 
eﬀ ects. The most common grade 3 or higher toxic eﬀ ects were fatigue (11 vs 9) and dyspnoea (three vs four).
Interpretation Thoracic radiotherapy in addition to prophylactic cranial irradiation should be considered for all 
patients with ES-SCLC who respond to chemotherapy.
Funding Dutch Cancer Society (CKTO), Dutch Lung Cancer Research Group, Cancer Research UK, Manchester 
Academic Health Science Centre Trials Coordination Unit, and the UK National Cancer Research Network. 
Introduction
Small-cell lung cancer accounts for 13% of all lung 
cancers, with the majority presenting at a stage of 
extensive disease.1 Chemotherapy is the cornerstone of 
treatment, and four to six cycles of platinum-based 
chemotherapy without maintenance treatment is the 
standard.2,3 However, survival for extensive stage 
small-cell lung cancer is poor, and has improved little in 
recent decades. Results of an analysis done in 
2000 showed a 2-year survival of less than 5%.1 Median 
time to progression is 4–6 months, and median survival 
is 7–11 months. Studies investigating other chemo-
therapeutic drugs, molecularly targeted drugs, or main-
tenance chemotherapy have not shown improvements.4,5 
Although most approaches have proven unsuccessful, 
a notable exception is prophylactic cranial irradiation 
following response to induction chemotherapy, which 
provided a survival beneﬁ t in a phase 3 trial.6 In this trial, 
the incidence of symptomatic brain metastases decreased 
signiﬁ cantly in the prophylactic cranial irradiation group 
compared with the control group (15% vs 40%), and 
survival at 1 year improved (27% vs 13%).
Intrathoracic tumour control remains a major 
diﬃ  culty for this disease. 75% of patients in the above 
mentioned study had persisting intrathoracic disease 
after chemo therapy, and roughly 90% had intrathoracic 
disease progression within the ﬁ rst year after diagnosis.6 
In a trial done at a single site,7 patients with extensive 
stage small-cell lung cancer who had a complete 
response at distant disease sites, and a complete or 
partial response locally, were randomly assigned to 
thoracic radiotherapy with low dose chemo therapy or 
additional chemotherapy only. The researchers reported 
a signiﬁ cant improvement in local control and survival 
following thoracic radiotherapy. Two retro spective 
analyses8,9 and one non-randomised phase 2 trial10 also 
suggest that thoracic radiotherapy is beneﬁ cial for 
patients. However, the level of evidence to recommend 
thoracic radiotherapy for patients who do not need 
immediate symptomatic palliation is low.3,4,11 We 
evaluated the role of thoracic radiotherapy in addition to 
prophylactic cranial irradiation for patients with 
extensive stage small-cell lung cancer who had 
responded to chemotherapy. 
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Methods
Study design and participants
We did this phase 3 randomised controlled trial at 
42 hospitals: 16 in Netherlands, 22 in the UK, three in 
Norway, and one in Belgium. Eligible patients had to 
satisfy the following criteria: age 18 years or older, WHO 
performance status 0–2, extensive stage small-cell lung 
cancer (deﬁ ned as disease beyond the hemithorax, hilar, 
mediastinal, and supraclavicular nodes12), any response 
after four to six cycles of standard chemotherapy 
(platinum etoposide) assessed in accord ance with 
standard local policy, thoracic treatment volume con-
sidered treatable using acceptable radiation ﬁ elds as 
judged by a radiation oncologist, 6 weeks or less between 
chemotherapy and randomisation, no clinical evidence 
of brain, leptomeningeal, or pleural metastases, no 
previous radiotherapy to brain or thorax, and ability to 
comply with protocol and follow-up schedules. All 
participants gave written informed consent according to 
International Conference on Harmonisation and good 
clinical practice and national or local regulations. The 
study protocol was approved by the ethics committee of 
each participating institution.
Randomisation and masking
We randomly assigned enrolled patients (1:1) centrally 
by computer to either thoracic radiotherapy plus 
prophylactic cranial irradiation or prophylactic cranial 
irradiation only, using minimisation13 and stratiﬁ cation 
by institution and presence or absence of intrathoracic 
disease. Neither patients nor any investigators were 
masked to treatment allocation.
Procedures
After randomisation, participants gave a clinical history 
and had a physical examination, chest radiography, and 
CT scan of their thorax and upper abdomen. A CT or MRI 
scan of the brain was done for all patients with symptoms 
suggestive of brain metastases. Other sites of disease were 
re-evaluated at the discretion of the investigator. Response 
to chemotherapy was assessed by the local investigators 
with RECIST 1.1 criteria,14 with no central review. Patients 
in both groups were followed up at 6 weeks and 12 weeks, 
then once every 3 months, then once every 6 months after 
1 year. Investigations included at least medical history, 
physical evaluation, and chest radiography. Toxic eﬀ ects 
were recorded according to Common Terminology 
Criteria for Adverse Events (version 3.0). We also recorded 
patterns of failure. Treatment for subsequent disease 
progression was not part of the protocol and was left to 
each centre’s policy, but all such patients were required to 
be followed up until death. 
Prophylactic cranial irradiation was given as 20 Gy in 
ﬁ ve fractions, 25 Gy in ten fractions, or 30 Gy in ten, 12, or 
15 fractions. Each centre had to preselect one prophylactic 
cranial irradiation scheme for all patients. Treatment was 
delivered with two opposed lateral ﬁ elds (4–10 MV). 
Thoracic radiotherapy was delivered to a dose of 30 Gy in 
ten fractions. The planning target volume included the 
post-chemotherapy volume with a 15 mm margin to 
account for microscopic disease and setup errors. Hilar 
and mediastinal nodal stations that were considered 
involved pre-chemotherapy were always included, even in 
case of response. Both 2D and 3D radiotherapy planning 
techniques were allowed. For 3D planning, the volume of 
normal lung tissue, minus planning target volume 
receiving more than 20 Gy, should be less than 35% and 
correction for tissue heterogeneity was mandatory. 
Treatment was delivered with a linear accelerator (4–10 MV) 
and all ﬁ elds were treated daily (four or ﬁ ve fractions per 
week). Prophylactic cranial irradiation and thoracic 
radiotherapy preferably had to start within 6 weeks, but not 
later than 7 weeks after chemotherapy, and not within 
2 weeks after chemotherapy or if acute grade 2 or higher 
toxic eﬀ ects of chemotherapy had not yet resolved. 
Outcomes
The primary endpoint was overall survival at 1 year. 
We also planned to analyse median overall survival and 
overall survival at 2 years. Secondary endpoints were 
intrathoracic control, pattern of failure, progression-free 
survival (median and at 6 months), and toxic eﬀ ects. We 
did a post-hoc analysis of overall survival at 18 months. 
All outcomes were assessed in the intention-to-treat 
population.
Statistical analysis
Based on the 27% 1-year survival reported in an EORTC 
study of prophylactic cranial irradiation in a similar group 
of patients,5 our study was powered to detect a 10% 
improvement in overall survival at 1 year from random-
isation (hazard ratio [HR] 0·76). Assuming a 5% dropout 
between randomisation and end of treatment, 483 patients 
had to be randomly assigned to obtain 80% power against 
this expected diﬀ erence (two-sided α=0·05). 
We calculated overall survival as time from randomisation 
to death. We calculated progression-free survival as time 
from randomisation to progression or death (whichever 
came ﬁ rst). Patients still alive without progression at the 
time of analysis were censored. We used the Kaplan-Meier 
method to estimate survival, and the log-rank two-sided 
test to compare groups. We summarised compliance to 
treatment allocation with the following parameters: 
proportion of patients who completed thoracic radio-
therapy, reasons for non-completion, proportion of 
patients in whom thoracic radiotherapy had to be delayed, 
and reasons for delays. We tested the interaction of 
treatment and selected factors with Cox proportional 
hazard analysis. We calculated the number of patients 
needed to treat to beneﬁ t on the basis of 2-year survival 
estimates.15 We deemed a two-sided p value of less than 
0·05 as statistically signiﬁ cant. 
This study is registered with the Nederlands Trial 
Register, number NTR1527.
For the adverse events 
criteria see http://ctep.cancer.
gov/reporting/ctc.html
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
Between Feb 18, 2009, and Dec 21, 2012, we randomly 
assigned 498 patients (249 in each group; ﬁ gure 1). The 
analysis was done in December, 2013; median follow-up 
was 24 months. 201 patients in the thoracic radiotherapy 
group died compared with 224 in the control group, with 
231 versus 239 progression-free survival events.
The mean interval between start of chemotherapy and 
randomisation was 15 weeks (range 14–19); the mean 
interval between diagnosis and randomisation was 
17 weeks (16–21). Baseline characteristics were much the 
same in each group (table 1). 22·9% of patients were 
over 70 years and 7·8% were over 75 years. The diagnosis 
of extensive stage disease was based on the presence of 
distant metastases in 378 patients (76·4%), the extent of 
intrathoracic disease in 34 patients (6·9%), or both 
factors in 83 patients (16·8%). No patients had brain, 
lepto meningeal, or pleural metastases. 230 (46%) of 
asymptomatic patients underwent a brain CT or 
MRI according to local policy. After completion of 
chemotherapy, a CT of the thorax was done for 482 (97%) 
patients and a brain CT or MRI in 43 (13%) of 
asymptomatic patients.
Chemotherapy consisted of a platinum etoposide 
combination for 488 (99%) patients, with seven patients 
receiving other platinum-based regimens. Nine patients 
did not receive or stopped prophylactic cranial irradiation 
(six had disease progression, two had deterioration of 
general health, and one patient refused), six in the thoracic 
radiotherapy group and three in the control group. In the 
thoracic radiotherapy group, seven patients did not receive 
and six did not complete thoracic radiotherapy, because of 
disease progression (n=5), deterioration of general 
condition (n=3), patient refusal (n=4), or treatment-related 
toxic eﬀ ects (n=1). The mean interval between last 
chemotherapy and prophylactic cranial irradiation was 
32 days. Prophylactic cranial irradiation was delivered as 
20 Gy in ﬁ ve fractions for 300 patients (62%), 25 Gy in 
ten fractions for 105 patients (22%), 30 Gy in ten fractions 
for 65 patients (14%), and 30 Gy in 12–15 fractions for 
15 patients (3%). For 240 (88%) patients in the thoracic 
radiotherapy group, thoracic radiotherapy was combined 
with prophylactic cranial irradiation. Thoracic radio therapy 
was started 1 week before prophylactic cranial irradiation 
for ﬁ ve (2%) patients, and thoracic radiotherapy was 
started for 13 patients (5%) within 7 days or less or on 
average 1 week after prophylactic cranial irradiation for all 
other patients (n=235, 98%). Grade 3 or higher toxic eﬀ ects 
occurred in 26 patients in the thoracic radiotherapy group 
and 18 patients in the control group (p=0·28, table 2).
Overall survival at 1 year was 33% (95% CI 27–39) in the 
thoracic radiotherapy group versus 28% (95% CI 22–34) in 
the control group: the diﬀ erence between groups was not 
signiﬁ cant (HR 0·84, 95% CI 0·69–1·01, p=0·066; ﬁ gure 2). 
Median overall survival was 8 months in both groups. At 
18 months, survival was 16% versus 9% (p=0·03). At 
2 years, survival was 13% (95% CI 9–19) in the thoracic 
Thoracic radiotherapy group (n=247) Control group (n=248)
Median age (IQR, years) 63 (58–69) 63 (57–69)
Age <75 years 233 (94%) 226 (91%)
Age ≥75 years 16 (6%) 23 (9%)
Median time to diagnosis (IQR, months) 3·7 (3·2–4·4) 3·7 (3·2–4·4)
Sex
Men 135 (55%) 136 (55%)
Women 112 (45%) 112 (45%)
WHO performance score
0 97 (39%) 70 (28%)
1 121 (49%) 155 (63%)
2 29 (12%) 23 (9%)
Response after chemotherapy
Complete response 12 (5%) 13 (5%)
Partial response 180 (73%) 170 (69%)
Good response 55 (22%) 65 (26%)
Persistent intrathoracic disease 215 (87%) 219 (88%)
Data are median (IQR) or n (%). Data are unavailable for smoking status.
Table 1: Baseline characteristics
249 allocated to thoracic
 radiotherapy
249 allocated to no 
 thoracic radiotherapy
247 analysed 248 analysed
498 randomly assigned
2 withdrew consent 1 withdrew consent
Figure 1: Trial proﬁ le 
Thoracic radiotherapy group (n=247) Control group (n=248)
Cough (grade 3) 0 (0·0%) 1 (0·4%)
Dysphagia (grade 3) 1  (0·4%) 0 (0·0%)
Dyspnoea (grade 3) 3 (1·2%) 4 (1·6%)
Oesophagitis (grade 3) 4 (1·6%) 0 (0·0%)
Fatigue (grade 3) 11 (4·5%) 8 (3·2%)
Fatigue (grade 4) 0 (0·0%) 1 (0·4%)
Insomnia (grade 3) 3 (1·2%) 2 (0·8%)
Nausea or vomiting (grade 3) 1 (0·4%) 0 (0·0%)
Headache (grade 3) 3 (1·2%) 2 (0·8%)
Table 2: Grade 3 and higher toxic eﬀ ects
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radiotherapy group and 3% (95% CI 2–8) in the control 
group (p=0·004). The number of patients needed to treat 
to avoid one death was 10·6 (95% CI 6·1–42·5).
Median survival was signiﬁ cantly diﬀ erent between 
patients in whom diagnosis of extensive stage disease was 
on the basis of intrathoracic disease only (11·8 months), 
distant metastases (7·5 months), or both factors 
(8·3 months; p<0·0001). We recorded no signiﬁ cant 
diﬀ erences in overall survival in subgroups divided by 
presence of intrathoracic disease at randomisation, sex, 
age, response to chemo therapy, WHO performance 
score, or extent of disease (ie, whether extensive stage 
disease was diagnosed on the basis of distant metastases, 
volume of intrathoracic tumour, or both (ﬁ gure 3). 
Progression was less likely in the thoracic radiotherapy 
group than in the control group (HR=0·73, 95% CI 
0·61–0·87, p=0·001; ﬁ gure 4). Progression-free survival at 
6 months was 24% (95% CI 19–30) for the thoracic 
radiotherapy group and 20% (95% CI 16–26) in the control 
group (p=0·001). Median progression-free survival was 
4 months for the thoracic radiotherapy group and 
3 months for the control group. In a test for interaction of 
factors with treatment, there was no signiﬁ cant diﬀ erence 
in the eﬀ ect of thoracic radiotherapy on progression-free 
survival for presence of intrathoracic disease at random-
isation (p=0·11), sex (p=0·12), age (p=0·19), response to 
chemotherapy (p=0·92), WHO performance score 
(p=0·94), and extent of disease (p=0·78). 
Isolated intrathoracic progression was rarer in the 
thoracic radiotherapy group (n=49, 19·8%) than in the 
control group (n=114, 46·0%, p<0·0001). Intrathoracic 
progression either with or without progression elsewhere 
occurred in 108 (43·7%) in the thoracic radiotherapy 
group versus 198 (79·8%) in the control group (p<0·0001). 
Brain metastases occurred in 24 (9·7%) versus 13 (5·2%; 
p=0·09), and disease progression at other sites occurred 
in 149 (60·3%) versus 100 (40·3%; p<0·0001). Table 3 
shows patterns of progression. We considered pro-
gression occurring at diﬀ erent organ sites within 30 days 
as simultaneous progression. The thorax was the ﬁ rst 
site of disease progression for 103 (41·7%) patients in 
the thoracic radiotherapy group versus 193 (77·8%) in the 
control group (p=0·009).
Discussion
The addition of thoracic radiotherapy to prophylactic 
cranial irradiation for patients with extensive stage 
small-cell lung cancer did not improve survival at 1 year. 
However, 2-year overall survival was signiﬁ cantly 
improved and progression-free survival was signiﬁ cantly 
greater. Further more, we report an almost 50% reduction 
in intrathoracic recurrences. These positive results are 
consistent with ﬁ ndings from studies of patients with 
locally advanced non-small-cell lung cancer showing that 
improved local control leads to improved survival.16
As might be expected from treatment of metastatic 
extensive stage small-cell lung cancer, overall survival 
was much the same in both groups during the ﬁ rst 
9 months, but a signiﬁ cant diﬀ erence in favour of the 
thoracic radiotherapy emerged at 2 years. 1 year survival 
for patients who received prophylactic cranial irradiation 
only was similar to that of patients who received only this 
treatment in an EORTC study6 (27·1% versus 27·6%), 
suggesting that our ﬁ ndings are representative and 
applicable to patients with extensive stage small-cell lung 
cancer. We measured median survival and 2 year survival 
from the time of randomisation, which was about 
4 months after the start of chemotherapy. As such, our 
Number at risk
Thoracic radiotherapy
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Control group
0
247
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6
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5
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7
1
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0·6
0·8
1·0
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al
Thoracic radiotherapy group
Control group
Figure 2: Kaplan-Meier curves for overall survival 
Hazard ratio 
(CI)*
Thoracic 
radiotherapy
Control
Intrathoracic disease
 Yes
 No
Sex
 Men
 Women
Age (years)
 36–70
 71–85
Response to chemotherapy
 CR
 PR
 Good response
WHO performance status
 0
 1
 2
Extensive disease based on
 Intrathoracic disease
 Distant metastases
 Both
Total
p 
value
0·35
0·06
0·58
0·58
1·00
0·86
 195/215
 29/33
 122/136
 102/112
 170/189
 54/59
 12/13
 153/170
 59/65
 65/70
 136/155
 23/23
 9/15
 172/188
 43/45
 224/248
Events/patients Events/patients
 175/213
 26/34
 115/135
 86/112
 152/193
 49/54
 10/13
 148/179
 43/55
 74/97
 101/121
 26/29
 11/19
 161/190
 29/38
 201/247
 0·80 (0·61−1·05)
 1·09 (0·54−2·18)
 1·01 (0·72−1·41)
 0·68 (0·46−1·00)
 0·82 (0·61−1·09)
 0·96 (0·58−1·60)
 1·38 (0·45−4·22)
 0·81 (0·60−1·10)
 0·76 (0·45−1·28)
 0·85 (0·55−1·32)
 0·84 (0·60−1·18)
 0·83 (0·39−1·78)
 0·68 (0·20−2·31)
 0·87 (0·66 −1·16)
 0·89 (0·48−1·65)
 0·84 (0·69−1·02)
10 1·5 20·5
Favours controlFavours thoracic
radiotherapy
Figure 3: Overall survival at 1 year in subgroups
*CI is 99% for subgroups, 95% for total. CR=complete response. PR=partial response.
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ﬁ ndings have to be considered in the context of other 
trials for extensive stage disease17–19 that reported survival 
of 8·1–10·6 months, measured from diagnosis. Median 
survival in our trial was 8 months from randomisation 
and about 12 months from diagnosis, but, since only 
responding patients were included, comparison with 
other studies is diﬃ  cult.
Thoracic radiotherapy was well tolerated and we recorded 
no severe acute or late toxic eﬀ ects. Compliance was high, 
with 95% of patients completing protocol-speciﬁ ed 
thoracic radiotherapy without interruption, and just 
one patient stopped thoracic radiotherapy before 
completion because of treatment-related toxic eﬀ ects. By 
contrast with the EORTC study of prophylactic cranial 
irradiation, which used an inclusion age limit of 75 years, 
we used no age restrictions. 8% of patients were older than 
75 years, making the ﬁ ndings of our study more applicable 
to the general population of patients with extensive stage 
small-cell lung cancer.
At present, standard treatment for patients with 
extensive stage small-cell lung cancer consists of four to 
six cycles of platinum-based chemo therapy, followed 
by prophylactic cranial irradiation for responding 
patients.2,3 Although 70–85% of patients respond after 
chemotherapy, with a complete response in up to 25% of 
cases, almost all patients relapse.4 Furthermore, response 
and survival after second-line chemotherapy is very poor 
and the use of systemic treatments in the past two 
decades has done little to improve ouctomes.2 By contrast, 
radiotherapy has survival advantages in both limited and 
extensive stage small-cell lung cancer.20,21 Prophylactic 
cranial irradiation improves survival of patients with 
extensive stage small-cell lung cancer.6 Although most 
patients have persistent intrathoracic disease after 
chemotherapy, thoracic radiotherapy is generally not 
considered because of the spread of disease outside the 
thorax, and is reserved for palliation of symptoms.
The use of thoracic radiotherapy for extensive stage 
small-cell lung cancer was investigated previously in a 
single-institution randomised study including 210 patients, 
done between 1988 and 1993, which suggested a beneﬁ t of 
thoracic radiotherapy for extensive stage disease (panel).7 
Initial treatment consisted of three cycles of cisplatin-
etoposide, and 206 patients were fully assessable for toxic 
eﬀ ects and survival. Only 109 patients from two favourable 
subgroups, namely those with complete response at both 
local and distant levels (n=55), and those with partial 
response within the thorax accompanied by complete 
response elsewhere (n=54), were considered for enrolment. 
Patients were randomly assigned to thoracic radiotherapy 
(54 Gy in 36 fractions delivered twice per day concurrently 
with chemotherapy, or chemotherapy alone).7 Patients who 
received thoracic radiotherapy had both higher median 
survival (17 months vs 11 months) and 5-year survival 
(9·1% vs 3·7%) than did those who did not receive thoracic 
radiotherapy. These survival rates are the highest of any 
reported in a randomised study of the disease, and result 
from selection of a favourable patient population. By 
contrast, only 5% of patients in our study had a complete 
response recorded at the time of randomisation.
Our results are broadly in line with retrospective8,9 and 
non-randomised10 studies of thoracic radiotherapy. In a 
retrospective review of 215 patients with extensive stage 
small-cell lung cancer, 19 patients received consolidative 
thoracic radiotherapy.8 In this favourable subset of 
patients with one or two metastatic sites, locoregional 
failure was reported in 26% at 1 year and 39% at 2 years.8 
Investigators of another retrospective study including 
119 patients did a multivariate analysis and reported an 
improvement in median survival for patients receiving 
thoracic radiotherapy.9 In a prospective non-randomised 
phase 2 study of patients with extensive stage small-cell 
lung cancer given four cycles of platinum-based chemo-
therapy, subsequent consolidative thoracic radiotherapy 
delivered as 40 Gy in 15 daily fractions was well tolerated, 
and only ﬁ ve of 32 patients developed a symptomatic 
chest recurrence.10 
Our results must be considered in the context of the 
strengths and weakness of the study design. A planning 
Thoracic radiotherapy group (n=247) Control group (n=248)
Any site 213 (86·2%) 223 (89·9%)
Thorax only 49 (19·8%) 114 (46·0%)
Thorax and brain 5 (2·0%) 3 (1·2%)
Thorax and other sites 50 (20·2%) 77 (31·0%)
Thorax, brain, and other sites 4 (1·6%) 4 (1·6%)
Brain only 10 (4·0%) 6 (2·4%)
Brain and other sites 5 (2·0%) 0 (0·0%)
Other sites only 90 (36·4%) 19 (7·6%)
Progression occurring at diﬀ erent organ sites within 30 days was considered as occurring simultaneously.
Table 3: Recurrences
Number at risk
Thoracic radiotherapy
group
Control group
0
247
248
3
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126
6
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9
31
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8
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9
3
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0·4
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0·8
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Figure 4: Kaplan-Meier curves for progression-free survival 
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CT scan of the thorax was only mandatory in case of large 
volume disease, which could have resulted in sub optimum 
doses of radiation delivered to some patients. However, the 
prescribed dose of 30 Gy in ten fractions is often delivered 
using opposed anterior and posterior ﬁ elds, with low 
likelihood of missing the target. More than 40% of patients 
who received thoracic radiotherapy had an intrathoracic 
recurrence, which might suggest that even higher doses of 
radiation, as assessed in previous studies,7–10 might be 
more eﬃ  cacious. A dose of 30 Gy in ten fractions is an 
accepted high palliative dose in lung cancer and is 
associated with few toxic eﬀ ects.22 The eﬀ ect of thoracic 
radiotherapy on overall survival in this study opens the way 
for further studies assessing higher doses of radiation and 
using advanced delivery techniques. However, many 
patients in our study had extrathoracic disease progression 
within the ﬁ rst year after treatment. A fractionation 
scheme of 30 Gy in ten fractions, or 40 Gy in 15 fractions, 
seems to oﬀ er a good balance between expected beneﬁ t, 
risk of side-eﬀ ects, and burden of treatment in this 
vulnerable group of patients with a poor prognosis. 
A limitation of this study was the absence of 
patient-reported outcomes. Evaluation of quality of life in 
these patients is challenging, and reported quality of life 
might reﬂ ect the disease more than the treatment itself. 
However, future studies of higher, potentially more toxic, 
radiation doses might beneﬁ t from studying patient-
reported outcomes.
Almost all patients had a diagnostic CT scan of the 
thorax to assess response to chemotherapy, but detailed 
restaging of other sites of disease was not mandated to 
assess response, because detailed re-staging after 
chemotherapy is not standard practice for extensive stage 
small-cell lung cancer. The use of a practical minimum 
requirement of at least a response within the thorax, 
even if not meeting the formal criteria for a partial 
response, can be easily implemented in clinical practice. 
We think that this approach, previously used in the 
EORTC prophylactic cranial irradiation study,6 might 
make the study results more generalisable to daily 
clinical practice. Indeed such a pragmatic study led to 
changes in routine practice within a few months of the 
study’s publication.23 
Because many patients have progression outside the 
thorax and brain despite thoracic radiotherapy, the 
addition of radiotherapy to sites of extrathoracic disease 
might also merit investigation.11 Such an approach is 
being investigated by the Radiation Therapy Oncology 
Group in a phase 2 study (ClinicalTrials.gov number 
NCT01055197). In this study, prophylactic cranial 
irradiation and thoracic radiotherapy are combined with 
radiotherapy to up to four extrathoracic metastases. 
Furthermore, molecularly targeted drugs that might be 
combined with radiotherapy are being investigated.5
For the present, our results show that thoracic 
radiotherapy improves long-term survival. Therefore, 
thoracic radiotherapy should be considered for patients 
with extensive stage small-cell lung cancer who have 
responded to chemotherapy.
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Panel: Review in context
Systematic review
We searched PubMed and the Cochrane Library databases 
without language restrictions for studies published between  
Jan 1, 1990 and Jan 1, 2014, with the terms “small cell lung 
cancer”, “extensive”, and “radiotherapy” or “radiation 
therapy”. We also searched clinical trial registers (ClinicalTrials.
gov and WHO International Clinical Trials Registry Platform) 
for ongoing trials and searched reference lists of relevant 
publications. We excluded retrospective studies and found 
one published randomised trial.7 This trial showed a survival 
beneﬁ t for patients with extensive stage small-cell lung 
cancer given thoracic radiotherapy in combination with 
chemotherapy, in a highly selected group of patients with a 
complete response outside the thorax and a partial or 
complete response in the thorax. 
Interpretation
Our ﬁ ndings suggest that the addition of thoracic 
radiotherapy after any response to chemotherapy in patients 
with extensive stage small-cell lung cancer leads to a 
signiﬁ cant reduction in intrathoracic recurrence and, despite 
the lack of a signiﬁ cant beneﬁ t in overall survival at 1 year, 
there were signiﬁ cant improvements in overall survival at 
2 years and progression-free survival at 6 months.
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